Introduction
============

Muscular dystrophies (MD) are genetically determined myopathies associated with histologic evidence of dystrophic changes seen on a muscle biopsy. [@JR_1] Many of the proteins affected in muscular dystrophies can be localized to the sarcolemma, and their complete or partial deficiency is diagnostic. This can be identified using immunohistochemistry (IHC) which can be performed on frozen muscle biopsy tissue and permits rapid diagnosis. [@BR_2] [@BR_3] [@JR_4] [@JR_5] [@JR_6] [@JR_7]

Immunohistochemical antibodies for diagnosing presence or absence of proteins including dystrophin, the sarcoglycan complex (α, β, γ, and δ), emerin, dysferlin, and merosin (laminin α 2) are currently available for use in muscle biopsy tissue. This allows the potential specific diagnosis of Duchenne and Becker MD, sarcoglycanopathies, Emery--Dreifuss MD, dysferlinopathy, miyoshi myopathy, and congenital MD. [@BR_2] Loss of calpain-3 antibody (for diagnosing LGMD2A) can be currently detected by western blotting, not by IHC. [@JR_8] However, for certain LGMDs like LGMD2L characterized by mutations in *ANO5* gene, antibody testing is not available and they can currently be detected by mutation analysis alone. [@JR_8]

Routine histopathologic examination of muscle biopsy provides information about the architecture and can reveal dystrophic changes in muscle biopsies; however, the type of muscular dystrophies cannot be categorized on routine histopathology alone. IHC is helpful in identifying the presence or lack of specific proteins and can categorize the vast group of muscular dystrophies. Genetic studies show higher sensitivity for variation in protein expression but are technically difficult and expensive. Moreover, genetic studies can be used to assess dystrophinopathies alone and are not widely available in nonresearch settings for other muscular dystrophies. Second, numerous mutations exist which may cause loss of a single muscle protein; hence, it is not always feasible to perform genetic analysis for multiple mutations in these cases as it is labor intensive and time consuming. [@BR_2]

The full-length dystrophin protein is a high molecular mass protein with four main domains. [@BR_2] Among mutations in the dystrophin gene, about two-thirds are deletions, 5 to 10% are duplications and the remainder are point mutations. These point mutations are difficult to identify with standard polymerase chain reaction but IHC easily identifies all mutations that lead to the formation of a stop codon and hence absence of protein. [@BR_2] Among molecular tests available for muscular dystrophy diagnosis are multiplex ligation probe amplification (MLPA), array-based comparative genomic hybridization (CGH) and next generation sequencing (NGS, [Table 1](#TB_1){ref-type="table"} ). [@JR_9] [@JR_10] [@JR_11] [@JR_12] [@JR_13] [@JR_14] [@JR_15] [@JR_16] [@JR_17] [@JR_18] [@JR_19] [@JR_20] [@JR_21]

###### Comparison of various tests available for diagnosis of muscular dystrophies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 IHC analysis                                                                                                            Western blotting                                                                                                                                                                                      Multiplex PCR                                                              MLPA                                                                                              cGH                                                                          NGS
  ------------------------------ ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------
  Sample requirements            Fresh frozen muscle biopsy tissue                                                                                       Fresh frozen muscle biopsy tissue                                                                                                                                                                     Whole blood                                                                Whole blood, chorionic villi, and muscle biopsy                                                   Whole blood                                                                  Whole blood

  Procedure specifications       Muscle biopsy procedure comparatively expensive and invasive may require general anesthesia in children                 Muscle biopsy procedure comparatively expensive, invasive, may require general anesthesia in children                                                                                                 Inexpensive blood sample collection                                        Inexpensive blood sample collection                                                               Inexpensive blood sample collection                                          Inexpensive blood sample collection

  Availability of test           Performed in specialized laboratories                                                                                   Performed in specialized laboratories                                                                                                                                                                 Performed in specialized laboratories                                      Performed in specialized laboratories                                                             Performed in specialized laboratories                                        Performed in high end research settings

  Time required                  About six person hours                                                                                                  Overnight                                                                                                                                                                                             Overnight                                                                  2 days                                                                                            4 days                                                                       Hours to days (depending upon platform used)

  Instrumentation required       Manual or automated IHC autostainer                                                                                     SDS-polyacrylamide gel electrophoresis system and Densitometry                                                                                                                                        PCR analyzers                                                              PCR followed by genetic analysis                                                                  Oligonucleotide probe hybridization, image scanning, and software analysis   Next generation sequencer. Available sparingly in high end laboratories.

  Standardization of procedure   Easy                                                                                                                    Easy                                                                                                                                                                                                  Easy                                                                       Difficult\                                                                                        Difficult                                                                    Difficult. Requires expertise in data analysis.
                                                                                                                                                                                                                                                                                                                                                                                                                                          Requires expertise in data analysis                                                                                                                                            

  Current availability for       Dystrophins, sarcoglycans, dysferlin, FKRP, merosin, emerin.\                                                           Calpain, Caveolin can be diagnosed in addition to those diagnosable by IHC                                                                                                                            Dystrophinopathies and sarcoglycanopathies                                 Dystrophinopathies and sarcoglycanopathies                                                        Dystrophinopathies and sarcoglycanopathies                                   Dystrophins mostly.\
                                 Calpain and caveolin cannot be diagnosed.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Mutation testing is currently being tested for many LGMDs
                                 No antibody available for LGMD 2L with mutation in ANO5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Cost of test                   Low                                                                                                                     Moderate                                                                                                                                                                                              Moderate                                                                   Moderate (similar to PCR)                                                                         High                                                                         High

  Parameter tested               Final protein product                                                                                                   Final protein product                                                                                                                                                                                 Gene deletions                                                             Gene deletions or duplications excluding intronic rearrangements. Point mutations not detected.   Gene deletions or duplications including intronic rearrangements.\           Gene deletions, duplications and point mutations
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Point mutations not detected                                                 

  Sensitivity                    High.\                                                                                                                  High.\                                                                                                                                                                                                Detects almost 68.7% of dystrophinopathies                                 Detects almost 75% of dystrophinopathies                                                          High.\                                                                       High.\
                                 Tests protein presence or absence. Example total three proteins for dystrophin abnormalities.\                          Tests protein presence or absence. Example total three proteins for dystrophin abnormalities.\                                                                                                                                                                                                                                                                                     Tests each gene locus                                                        Can detect abnormality in entire genome
                                 Detects almost 100% of dystrophinopathies.                                                                              Detects almost 100% of dystrophinopathies. Detects LGMD 2A with approximately 53% sensitivity and 85% specificity.                                                                                                                                                                                                                                                                                                                                              

  Usability of test              Poor in advanced disease with fatty replacement of muscle.\                                                             Cannot differentiate small amounts of residual protein from revertant fiber protein expression. Secondary reduction of expression of associated proteins in LGMD requires caution in interpretation   Gene duplications not detected                                             About one third of MLPA negative cases had dystrophinopathy on muscle IHC                         Limit to the number of genes that can be tested simultaneously               Improves with availability of muscle biopsy protein analysis
                                 Useful in AR LGMD with loss of function; alteration or loss of one mutant allele is difficult to detect in AD forms.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                 Secondary reduction of expression of associated proteins in LGMD requires caution in interpretation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Prognostic value               Amount of membrane protein correlates better with patient phenotype                                                     Amount of membrane protein correlates better with patient phenotype                                                                                                                                   Does not predict phenotypic manifestation                                  Does not predict phenotypic manifestation                                                         Does not predict phenotypic manifestation                                    Does not predict phenotypic manifestation

  Use in therapeutic trials      Good for assessing outcome of therapeutic trials for restoring absent membrane proteins                                 Good for assessing outcome of therapeutic trials for restoring absent membrane proteins                                                                                                               Cannot predict phenotypic outcome; less likely to aid therapeutic trials   Cannot predict phenotypic outcome; less likely to aid therapeutic trials                          Cannot predict phenotypic outcome; less likely to aid therapeutic trials     Cannot predict phenotypic outcome; less likely to aid therapeutic trials
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Objectives
==========

The current study aimed to assess the profile of muscular dystrophies, characterize them using minimalistic immunohistochemical panels, and evaluate the cost effectiveness of IHC as compared with genetic studies in the diagnosis and categorization of muscular dystrophies in a resource-limited setting.

Materials and Methods
=====================

The present study was performed at two tertiary care referral hospitals: King George Medical University, Lucknow (KGMU) and Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow (RMLIMS). Consecutive clinically suspected cases of muscular dystrophies presenting at the departments of neurology at KGMU and RMLIMS were recruited over a period of 2 years. The biopsy analysis was performed at the department of pathology, RMLIMS.

1.  Clinical assessment: Detailed history included the following factors: age, sex, family history, age of onset, topography of muscle involvement, and presence of calf hypertrophy. Physical examination as well as manual muscle testing utilizing the Standard Medical Research Council grading system for the assessment of power of muscle and neuroelectrophysiology was done in each case. [@OR_22]

2.  Laboratory investigations: Routine hematological tests, serum calcium and creatine phosphokinase levels were evaluated in all cases.

3.  Muscle biopsy processing: Cases suspected to have muscular dystrophy based on history, clinical, and serological profile underwent muscle biopsy after informed consent. Patients with bleeding disorders or on anticoagulants, those with a recent history of muscle infection or trauma to the biopsy site and those with myopathies other than muscular dystrophy like inflammatory, hypothyroid, or osteomalacic myopathy were excluded from the study. A muscle showing moderate affliction was selected for biopsy. Open muscle biopsy was performed, and tissue transported without delay to the laboratory in a fresh state wrapped in saline moistened gauze, without any fixative. The tissue was divided into two equal portions. One portion was snap frozen in isopentane precooled in liquid nitrogen and serially sectioned in the cryostat. Sections were used for hematoxylin and eosin and IHC staining. The second portion was routinely processed in formalin and paraffin embedded.

4.  Immunohistochemical studies: These were performed on frozen muscle tissue using monoclonal antibodies to dystrophin N domain (1:20), dystrophin C domain (1:20), and dystrophin rod domain (1:5); sarcoglycans α, β, γ, and δ (all at a dilution of 1:20); dysferlin (1:25) and Merosin (1:50). All primary antibodies procured from Novocastra, United Kingdom. Frozen sections were hydrated with Tris-buffered saline and incubated in endogenous blocking solution for 30 minutes, followed by washing and incubation in primary antibody for 2 hours. Treatment with HRP-tagged secondary antibody (Envision system from Dako; Glosstrup, Denmark) was done for 30 minutes. Diaminobenzidine was used as substrate chromogen.

5.  Biopsy assessment: Morphologic features were evaluated using Hematoxylin and Eosin stained sections. Endomysial fibrosis was assessed using Masson Trichrome staining. Biopsies suggestive of muscular dystrophy on histomorphology were further categorized using IHC.

6.  IHC assessment: IHC panels were tailored according to the history and clinical profile of individual cases. Biopsies showing fixation artifacts or poor tissue preservation on H and E sections of frozen tissue were excluded from further IHC workup. Merosin staining was performed in all cases to ensure integrity of sarcolemmal membrane. Cases showing loss of merosin staining were excluded from further IHC evaluation. Parallel positive controls (from biopsies of known cases of inflammatory myopathies) were run in each case.

7.  Cost analysis: This was performed for the diagnostic panel used in our cases. Cost of biopsy procedure, and IHC was calculated for cases based on the effective cost at our Institute. For cost comparison, a representative cohort was used with the assumption that genetic and molecular testing were performed on blood samples alone and muscle biopsy was avoided. Standard cost of molecular and genetic tests in reputed laboratories was used for the purpose of comparison.

Statistical Analysis
--------------------

Descriptive statistics were used for data analysis. Mean and standard deviation were used for continuous variables, whereas categorical variables were analyzed using frequency percentage. A *p* -value was calculated for the association of clinical and histological findings with the final diagnosis.

Results
=======

A total of 47 muscle biopsies from suspected cases of muscular dystrophies were received. Histomorphology of all biopsies showed features of dystrophy which included presence of fibrosis in the endomysium, rounded fibers with variable muscle fiber size, numerous internal nuclei, and presence of degenerating and regenerating fibers. Few cases showed split fibers and endomysial inflammation in addition. Of the 47 cases, five cases showed poor tissue preservation on H and E sections, and were excluded from further IHC analysis. Results of IHC analysis on muscle biopsies of these patients, and their clinical features are presented in [Table 2](#TB_2){ref-type="table"} . The clinical, electrophysiological, and biochemical features of the cases are presented in [Table 3](#TB_3){ref-type="table"} .

###### Various muscular dystrophies classified on IHC and their clinical data

  Diagnosis                                           Number of cases   Mean age ±SD (y) at presentation   Male: Female Ratio   Positive Family History (number of cases)
  --------------------------------------------------- ----------------- ---------------------------------- -------------------- -------------------------------------------
  Dystrophinopathy                                    13                9.92 ± 2.43                        12:1                 2
   DMD                                                9                                                                         
   Becker's dystrophy                                 3                                                                         
   Dystrophinopathy carrier                           1                                                                         
  Sarcoglycanopathy                                   10                20.6 ± 10.09                       9:1                  2
   Sarcoglycan α                                      1                                                                         
   Sarcoglycan β                                      7                                                                         
   Sarcoglycan γ                                      0                                                                         
   Sarcoglycan δ                                      2                                                                         
  Dysferlinopathy                                     1                 24                                 1:0                  0
  MD not further categorized                          18                                                                        
   MD Dystrophinopathy & sarcoglycanopathy excluded   16                24 ± 13.5                          1.2:1                2
   MD FSHD                                            2                 25 ± 15.5                          1:1                  0
  Total cases analyzed                                42                18.8                               5:1                  6

###### Clinical, electrophysiological and biochemical features of the muscular dystrophies

  S No.   Type of muscular dystrophy                           Lower limb weakness   Upper limb weakness   Facial weakness   Calf hypertrophy   Myopathic pattern on electromyography   Nerve conduction studies   Mean serum CPK (U/L)   Serum calcium (g/dL)
  ------- ---------------------------------------------------- --------------------- --------------------- ----------------- ------------------ --------------------------------------- -------------------------- ---------------------- ----------------------
  1\.     Dystrophinopathy                                     13                    7                     0                 6                  11                                      Normal                     4,904 ± 3,342          9.7
  2\.     Sarcoglycanopathy                                    10                    5                     0                 3                  8                                       Normal                     4,264 ± 2,023          9.6
  3\.     Dysferlinopathy                                      1                     1                     0                 0                  1                                       Normal                     3,456                  9.4
  4\.     Muscular dystrophy not further categorized                                                                                                                                                                                      
          MD dystrophinopathy and sarcoglycanopathy excluded   14                    12                    0                 1                  13                                      Normal                     3,174 ± 2,446          9.2
          MD FSHD                                              0                     2                     2                 0                  1                                       Normal                     3,193 ± 3,498          9.3
  5\.     Total cases analyzed                                 38                    27                    2                 10                 34                                                                 4,642 average          9.4 average

Dystrophinopathies
------------------

A total of 13 cases showed absence or diminution of sarcolemmal dystrophin staining and were grouped as dystrophinopathies. Of these, nine showed complete absence of N, C, and Rod domain staining, and were consistent with a diagnosis of Duchenne muscular dystrophy (DMD). Along with dystrophins mild secondary reduction of sarcoglycans α and β was also seen in one of the DMD cases. Three cases showed weak but retained membrane staining for one or more of the three dystrophin antibodies, and were consistent with Becker's muscular dystrophy. A single female patient showed reduced staining for dystrophin panel and was diagnosed as DMD carrier.

Sarcoglycanopathies
-------------------

Ten cases showed abnormal sarcoglycan staining and grouped as sarcoglycanopathies. Seven cases were categorized as β sarcoglycanopathy of which four showed complete absence, while three showed reduced immunostaining of β sarcoglycan. Secondary mild reduction of α sarcoglycan staining was also seen in four cases diagnosed as β sarcoglycanopathy. A single case of α sarcoglycanopathy was identified, which showed absence of α sarcoglycan staining with secondary mild reduction of β sarcoglycan. Two cases diagnosed as δ sarcoglycanopathy showed complete absence of δ sarcoglycan; of these, one case also showed secondary reduction of the other three sarcoglycans.

Dysferlinopathy
---------------

With complete absence of dysferlin, one case was diagnosed as having dysferlinopathy, staining for sarcoglycans and dystrophins being normal.

Muscular Dystrophy not further Categorized
------------------------------------------

A total of 18 cases showed no change in immunoreactivity in any of the IHC panels used. Among these, two cases were clinically suspected to be Fascioscapulohumeral dystrophy (FSHD) based on the pattern of muscle weakness. These were diagnosed as FSHD on the basis of histopathologic findings and exclusion of IHC abnormalities. Out of the remaining 16 cases, 14 showed presence of weakness in all four limbs and two showed presence of upper limb weakness alone. These cases could only be diagnosed as muscular dystrophy on histomorphology and could not be categorized further immunophenotypically.

The results obtained using our diagnostic approach to muscular dystrophies using IHC panels is presented in [Fig. 1](#FI-1){ref-type="fig"} .

![Patients presenting with features of muscular dystrophy (42). BMD, Becer's muscular dystrophy; DMD, Duchenne muscular dystrophy; EDMD, emery dreifuss muscular dystrophy; FSHD: fasciosc apulohumeral muscular dystrophy; SGP, sarcolgycanopathy.](10-1055-s-0040-1713301_00479_01){#FI-1}

Cost Minimization Analysis
--------------------------

An economic analysis was done in which we compared the net costs of determining the diagnosis and subtype of muscular dystrophies utilizing primarily muscle biopsy (with or without resort to subsequent genetic studies) versus using genetic analysis alone. The cost of methodologies of muscle biopsy (using IHC studies), and whole blood genetic analysis was compared to establish the cheapest alternative among them.

The minimum cost of diagnosing muscular dystrophies using a biopsy first approach (followed by use of genetic studies as required) was Rs 3,12,200, and minimum cost calculated for diagnosing all cases by genetic studies was Rs 5,79,600 which was significantly higher ( [Table 4](#TB_4){ref-type="table"} ).

###### Cost comparison using biopsy first and genetic analysis approaches for the diagnosis of muscular dystrophies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S.No        Diagnostic method used                                                                                                               Cost per test in INR   Number of cases tested   Total cost in INR
  ----------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------- ------------------------ -------------------------------------------------------------
  1           "Biopsy first" approach                                                                                                                                                              

  1a          Cost of biopsy procedure                                                                                                             300                    42                       12,600

  1b          Histology and immunohistochemistry studies                                                                                           1,400                  42                       58,800

  1c          Cost of genetic studies for cases left undiagnosed by histopathology and IHC                                                                                16                       

  1c(i)       Multiplex DNA PCR with Begg's and Chamberlain's primer                                                                               3,800                  16                       60,800

  1c(ii)      Comparative genomic hybridization                                                                                                    1,05,000               16                       16,80,000

  1c(iii)     Multiplex ligation probe amplification                                                                                               12,000                 16                       1,92,000

  1d          Cost of next generation sequencing for remaining 1/3 cases not diagnosed by above methods                                            30,000                 6                        1,80,000

              Total cost range (depending upon type of genetic study used) 1a+1b+1c (either of i, ii, or iii) + 1d                                                        42                       3,12,200 (i); 19,31,400 (ii); 4,43,400 (iii)

  2 a         "Nonbiopsy/ genetic analysis approach"                                                                                                                      42                       

  2b (i)      Using next generation sequencing alone                                                                                               30,000                 42                       12,60,000

  2 b (ii)    Multiplex DNA PCR with Begg's and Chamberlain's primer studies                                                                       3800                   42                       1,59,600

  2 b (iii)   Comparative genomic hybridization                                                                                                    1,05,000               42                       44,10,000

  2b (iv)     Multiplex ligation probe amplification                                                                                               12,000                 42                       5,04,000

  2c          Cost of next generation sequencing for remaining 1/3 cases not diagnosed by multiplex PCR/cGH/MLPA                                   30,000                 14                       4,20,000

              Total cost for nonbiopsy/genetic studies approach (depending upon type of genetic study used) 2b (either of i, ii, iii or iv) + 2c                          42                       12,60,000 (i); 5,79,600(ii); 48,30,000 (iii); 9,24,000 (iv)

              Incremental cost of genetic studies over the biopsy first approach\                                                                                         42                       2,67,400
              5,79,600--3,12,200                                                                                                                                                                   

              Minimal cost per patient diagnosed using biopsy first approach                                                                                              Per patient              7433

              Minimal cost per patient diagnosed using nonbiopsy/genetic studies approach                                                                                 Per patient              13,800
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

The current study analyzed 47 consecutive patients from all age groups, clinically diagnosed to have muscular dystrophy. The clinical, biochemical, muscle biopsy histopathology, and IHC profile of all cases was studied. A minimalistic IHC panel was tailored for each case based on the clinical history, examination, and histomorphology. The cost of biopsy first approach using IHC studies primarily was compared with cost required to diagnose and categorize muscular dystrophies using molecular tests, and the former method proved more cost effective.

Total 31% of all cases were categorized as dystrophinopathies, including DMD (69.2%), BMD (23%), and one female dystrophinopathy carrier. Of the 10 cases of sarcoglycanopathies (23% of total), 70% showed β, 10% α, and 20% δ sarcoglycanopathy; a solitary case of dysferlinopathy (2.3%) was diagnosed along with two cases of facioscapulohumeral dystrophy (4.7%). No case of Emery--Dreifuss disease was identified. Total 16 cases (38.1%) showing clinical and histologic evidence of muscular dystrophy could not be further categorized due to absence of immunohistochemical alterations in any of the IHC panels used.

Majority of dystrophinopathies were detected in children less than 10 years of age (mean age = 9.9 years). Similarly, in a study from Gujarat, India, the mean age of DMD patients was 10.75 years at presentation. [@JR_23] Most patients were males, relating to the X-linked inheritance. One female patient was diagnosed as a DMD carrier. Patients with sarcoglycanopathies had a mean age of 11.8 years at disease onset and 20.6 years at disease diagnosis. In a report from Northern India, mean age of sarcoglycanopathy patients was 7.2 years with age range of 5 to 20 years at onset of symptoms. [@JR_7] In another Indian study by Khadilkar et al, patients with sarcoglycanopathy had a mean age of 25.84 years (with age range of 8--42 years) and age at onset of symptoms was 15 years (with age range of 5--37 years). [@JR_4] In our series, cases with sarcoglycanopathy had a high male:female ratio of 9:1. Other series on sarcoglycanopathy have reported male: female ratios of 1.1:1 and 1.5:1. [@JR_6] [@JR_7] One male patient with dysferlinopathy and two cases of FSHD (one male and one female) were also diagnosed in our series. Positive family history could be obtained only in six cases (14.3%). Similarly, in a study on 106 dystrophinopathy patients, only 17% had a positive family history. [@JR_24]

The commonest presenting symptom was proximal symmetrical lower limb weakness (in 38 of 42 patients). Distal weakness was found in three cases, one of DMD and two which could not be categorized further. Ten patients presented with calf hypertrophy, including 46% cases of dystrophinopathy and 37.15% cases of sarcoglycanopathy. Rao et al found calf hypertrophy in 87% of dystrophinopathy cases. [@JR_23] A high proportion of sarcoglycanopathy cases also showed presence of calf hypertrophy including 69% cases reported by Sharma et al and 44% reported by Khalidar et al. [@JR_4] [@JR_7] Scapular winging was seen in four of our cases; among them two were FSHD, one DMD and two dystrophy cases which could not be categorized further.

In our study, the mean CK value was 4642.3 IU/L. In dystrophinopathy group, it was 4,904 IU/L (mean CPK of 5,568 IU/L in DMD and 4,486 IU/L in BMD patients). Similar elevated CK values have been reported in dystrophinopathies reported from Gujarat (mean CPK 7218.4 in DMD and 5,574 IU/L in BMD). [@JR_23] The sarcoglycanopathy patients showed a mean CPK of 4,264 IU/L in our series, whereas it was 7,853 IU/L in a series by Nalini et al. [@JR_6] The nerve conduction velocity was normal in all patients. Electromyography (EMG) pattern was myopathic in 80.9% cases among which dsytrophinopathy cases showed myopathic pattern in 84% cases and sarcoglcanopathy in 80% cases. One of the two FSHD cases and the dysferlinopathy case also showed myopathic pattern. In a study by Nalini et al, 65.1% of sarcoglycanopathy cases showed myopathic pattern on EMG. [@JR_6]

The MDs were diagnosed by the presence of "dystrophic" changes on muscle biopsy and further categorized using IHC on fresh frozen muscle biopsy tissue. In the present study, nine cases showed complete absence of dystrophin rod domain, C-terminus domain, and N-terminus domain (except for few revertant fibers); and were categorized as DMD. Incomplete patchy sarcolemmal immunostaining of dystrophin antibodies was seen in the three cases of BMD. Barresi et al also recommend the use of multiple antibodies focused at numerous sites of the large dystrophin molecule to prevent false negative results which may arise due to loss of epitopes away from the site recognized by a particular antibody. A panel of antibodies focused against N-terminal, C terminal or rod domain is hence routinely used for IHC. [@JR_25] A female carrier was also detected in our series based on patchy expression of dystrophin antibodies in the muscle biopsy. Among 106 suspected dystrophinopathy cases, Freund et al found immunohistochemical abnormalities on muscle biopsy in four females (one DMD patient and three carriers); however, none of these four could be detected using PCR on peripheral blood leucocytes.﻿﻿24﻿﻿ MLPA has also been reported to be of use in detecting female carriers where the male proband harbors a deletion or duplication of dystrophin gene. For point mutations, direct sequencing is reportedly a better method than MLPA analysis. [@JR_26]

In the present study, we could classify 10 cases (21% of all MD cases) as sarcoglycanopathy. Seven cases of β SGP, two of δ SGP, one of α SGP, one dysferlinopathy, and two FSHD were diagnosed. The reported incidence of sarcoglycanopathies among LGMD cases in India varies from 11.8 to 46.2%. [@JR_4] [@JR_7] It may be noted that whether this actually represented the LGMD genotype as a whole is doubtful. The lack of use of a uniform definition for including patients, as well as referral bias, impart a significant amount of heterogeneity to studies whereby no study from the Indian subcontinent could find a place in the meta-analysis and systematic review focused at detailing epidemiologic data on muscular dystrophies. [@JR_27]

Few studies on sarcoglycanopathies confirmed on IHC or genetic analysis are reported from India. The commonest IHC pattern in sarcoglycanopathies was that of loss of multiple sarcoglycans, in several series including ours. [@JR_4] [@JR_7] Multiple losses were noted in 70% cases in our study and ranged from 38.5 to 84% in other Indian series. [@JR_4] [@JR_7] Intricate interaction among the sarcoglycan subunits and destabilization of the complex is probably the basis for this. Similar to our study where 20% cases showed isolated loss of β sarcoglycan, Nalini et al reported loss of β sarcoglycan alone in 19% cases and Khadilkar et al in 12%. [@JR_4] [@JR_6] Deficient β sarcoglycan expression was followed by that of δ sarcoglycan in our study, similar to the findings of Khadilkar et al. [@JR_4] This is understandable since β and δ subunits form the core of the sarcoglycan complex. On the contrary, no case with isolated deficiency of β or δ sarcoglycan was noted among 13 cases reported from Delhi, where γ sarcoglycanopathy was followed in frequency by α sarcoglycanopathy. [@JR_7] IHC may hence guide genetic analysis by either defining an isolated affected gene or highlighting the one most severely affected from amongst multiple affected ones. [@JR_4] [@JR_7]

A single case of dysferlinopathy (3.5% of LGMD) and two of FSHD (7% of LGMD) were noted in our series, whereas they proportioned 10.2 and 28% respectively in a series by Sharma et al. [@JR_7] Data on these entities are not available from other large series from India. A large proportion of LGMD cases remained unclassified on IHC, this included 55% cases from our series, matched closely by 54% reported by Khadilkar and 49% by Sharma et al. [@JR_4] [@JR_7] This group may comprise either patients who have missense mutations in a SG gene (without change in protein expression) or nonsarcoglycan deficient forms of LGMD. Defects in several nonsarcoglycan genes presenting as LGMDs have been reported and include calpain, titin, dystroglycans, fukutin, and anoctamin 5 among others, which were not analyzed in the present study. [@JR_28] [@JR_29] IHC analysis is not available for use in muscle biopsy tissue for most of these and molecular analysis would be essential to ascertain the primary abnormality. However, currently IHC and western blotting are considered the gold standards for diagnosis of dysferlin, sarcoglycans, caveolin 3, and telethonin antibodies. [@JR_29]

Though data on calpainopathy is limited from India, a recent Indian study using immunoblotting identified 47% of all LGMD cases to be due to calpainopathy; this may mean that calpainopathy is the commonest form of LGMD in India, similar to recent epidemiologic data from across the globe. [@JR_30] Immunostaining prior to molecular analysis can identify approximately half of the protein abnormalities in cases presenting with LGMD, thereby allowing genetic analysis to focus on required genes. While supporting our findings, Nalini et al in their study also suggest that genetic testing is necessary for prenatal diagnosis of muscular dystrophies and genetic counselling. [@JR_6]

We also analyzed the cost of using IHC as a primary specific diagnostic tool versus direct genetic diagnostic approach ( [Table 4](#TB_4){ref-type="table"} ). It is clear from our analysis that the biopsy first approach was more economic than genetic studies.

There were some limitations of the present study. Total 47 cases were included in our study, but five cases could not be analyzed due to poor preservation of the tissue. In some cases, biopsy from severely affected muscle was sent which was completely replaced by fat and connective tissue, so IHC interpretation was not possible in those cases. We were unable to perform western blotting for detecting suspected calpainopathies due to unavailability of the antibody for our study. Though the cost of diagnosing muscular dystrophies using various methods was compared, the genetic analysis was not performed at our center and the applicable cost at other reputed centers in India was used for comparison. Such cost comparison performed on a larger group of patients would probably provide a more holistic cost benefit ratio.

Conclusion
==========

In conclusion, our study provided data on biopsy proven muscular dystrophies from two tertiary care centers in North India and compared their prevalence with data from other centers in India. Biopsy studies can be utilized for definite diagnosis of several muscular dystrophies and also narrow the differential diagnosis so that appropriate genetic studies can be planned. Genetic studies are currently of limited availability in India and are more expensive as compared with biopsy and IHC. Currently, no specific therapies exist for these muscular dystrophies. However, correct identification of the subtype aids prediction of subsequent phenotype and behavior of the disorder. Genetic and familial counseling can also be specifically directed. Moreover, targeted therapy may be available in the future with advancement in knowledge regarding these molecules. Using these methodologies sequentially with a "biopsy first approach" may be the prudent approach for low income countries.
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